Earnings call transcript: Asker Healthcare Q1 2026 sees strong growth, stock up

Asker Healthcare reported strong Q1 2026 results, with net sales up 13% year over year to SEK 4.5 billion and adjusted EBITDA up 21% to SEK 442 million, including 70 bps margin expansion to 9.8%. Operating cash flow rose to SEK 419 million, the stock jumped 8.93% pre-market, and management reiterated a steady M&A pipeline with expected Q2 cash outflows of about SEK 450 million for earn-outs plus SEK 149 million in dividends. FX remained a 4% headwind, but organic growth of 5%-8% and continued acquisition-driven expansion support the positive outlook.

Analysis

The key second-order read-through is that Asker is now compounding like a scaled distributor with a pricing umbrella, not just an acquirer. The combination of mid-single-digit organic growth, margin accretion from tuck-ins, and stable leverage implies the market may still be underestimating the durability of cash conversion through 2026 even with the Q2 earn-out/dividend cash drain. The stronger signal is not the quarter itself, but that management is explicitly saying the M&A funnel is deeper than capital capacity, which shifts the bottleneck from finding deals to timing them.

Competitive dynamics are favorable for Asker’s ecosystem and increasingly hostile for subscale regional distributors and specialty suppliers. Asker’s ability to extract operating leverage from newly acquired niches suggests smaller peers face a widening hurdle: they must either accept lower pricing power or sell into a consolidator that can spread procurement, logistics, and SG&A over a broader base. The new distribution center is an underappreciated medium-term lever; while it is a near-term cash drag, it should improve service reliability and route density, reinforcing customer stickiness just as larger contracts roll and renewal risk becomes more visible.

The main risk is that the market extrapolates an unusually clean organic-growth quarter into the wrong slope. Q2 will likely look mechanically softer on cash and potentially noisier on reported growth because of seasonality, earn-outs, and comparisons, but that is a financing issue more than an operating one. The real reversal risk is if FX stays adverse while deal cadence slows: then the story shifts from compounding to merely defending margin, and the stock could de-rate from a growth compounder to a stable distributor multiple.

Contrarian angle: the current move may still be underdone if investors focus only on headline EBITDA growth and miss the leverage on future M&A. Management’s comments imply 2026 should be a year of repeated small accretive adds, not a one-off burst, which supports a higher long-term multiple. The stock can keep re-rating if the market starts capitalizing the post-acquisition margin profile rather than just the current-year revenue line.

Key Decisions for Investors

• Long ASKR-SS / ASKR.ST on 3-6 month horizon: use post-earn-out/Q2 cash-outflow weakness as entry; thesis is cash noise masks durable margin compounding and M&A optionality, with upside if leverage stays below target and deal flow continues.
• Pair trade: long ASKR.ST vs short a regional European medical distribution peer basket over 6-12 months; Asker has better scale leverage, stronger acquisition currency, and more visible organic growth durability.
• Buy ASKR.ST on any 5-8% pullback after Q2 cash distribution headlines; risk/reward favors adding into temporary pressure because the market should eventually discount normalized free cash flow post-exit of one-time payouts.
• For defensive exposure, prefer long healthcare distribution over broad healthcare equipment manufacturers; Asker’s model has lower demand cyclicality and better pass-through, making it a better quality compounder if macro/FX volatility persists.
• If options are liquid, consider a 6-9 month call spread on ASKR.ST financed by selling upside further out of the money; this captures multiple re-rating from M&A visibility while limiting downside if Q2 cash flow creates a temporary de-rating.